Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Integrative Hematology Oncology Fellowship: A Descriptive Analysis of the First Accredited Program in the United States

Krisstina Gowin, Ashley Larsen, John Camoriano

Blood (2024) 144 (Supplement 1): 3826.

https://doi.org/10.1182/blood-2024-211011

Published: 2024

Journal Articles

Predictors of Individual Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study

Muhammad Ali Khan, Syed Arsalan Naqvi, Cecilia Y. Arana Yi, John Camoriano, Joshua Blocher, Jennifer Andres, Irbaz Bin Riaz, Jeanne Palmer

Blood (2024) 144 (Supplement 1): 5195.

https://doi.org/10.1182/blood-2024-212240

Published: 2024

Journal Articles

Patient Cost Savings When Using Telehealth for Management of Myeloproliferative Neoplasms

Muhammad Ali Khan, Syed Arsalan Naqvi, Cecilia Y. Arana Yi, John Camoriano, Leslie Padrnos, Jennifer Andres, Joshua Blocher, Irbaz Bin Riaz, Jeanne Palmer

Blood (2023) 142 (Supplement 1): 6409.

https://doi.org/10.1182/blood-2023-187931

Published: 2023

Journal Articles

Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination

Michael T. Francisco, Adrienne E. Kaufman, Donald Northfelt, Leslie Padrnos, Allison C. Rosenthal, Jennifer Andres, Jill Adamski, Theresa Kinard, John Camoriano

Blood (2021) 138 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2021-151964

Published: 2021

Journal Articles

Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need

Krisstina L. Gowin, Betsy Wertheim, Ashley Larsen, John Camoriano

Blood (2021) 138 (Supplement 1): 1887.

https://doi.org/10.1182/blood-2021-151413

Published: 2021

Journal Articles

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Jeanne M. Palmer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, John Camoriano, MD, Craig Zimmerman, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-138934

Published: 2020

Journal Articles

Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Jeanne Palmer, MD, Heidi E. Kosiorek, MS, Craig Zimmerman, PhD, Oleh Zagrijtschuk, MD, John Camoriano, MD, Ruben A. Mesa, MD

Blood (2018) 132 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2018-99-115521

Published: 2018

Journal Articles

Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience

Krisstina L. Gowin, DO, Tania Jain, MD, Heidi E. Kosiorek, MS, John Camoriano, MD, Raoul Tibes, MD, Jeanne Palmer, MD, Ruben A. Mesa

Blood (2015) 126 (23): 2818.

https://doi.org/10.1182/blood.V126.23.2818.2818

Published: 2015

Journal Articles

Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis

Krisstina L. Gowin, DO, Heidi E. Kosiorek, MS, Amylou Constance Dueck, PhD, John Mascarenhas, Ronald Hoffman, MD, Craig B. Reeder, MD, John Camoriano, MD, Veena Fauble, MD, Raoul Tibes, MD, Katherine Gano, MS, Vineta Ghurye, Patricia Koenig, Ruben A. Mesa

Blood (2015) 126 (23): 1618.

https://doi.org/10.1182/blood.V126.23.1618.1618

Published: 2015

Journal Articles

Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia

Krisstina L. Gowin, DO, Amylou C. Dueck, PhD, John O Mascarenhas, MD MS, Ronald Hoffman, MD, Craig B. Reeder, MD, John Camoriano, MD, Katherine Gano, MS, Vineta Ghurye, Sravan Nagi Reddy, Patricia Koenig, Veena Fauble, MD, Raoul Tibes, MD, Ruben Mesa, MD

Blood (2014) 124 (21): 3206.

https://doi.org/10.1182/blood.V124.21.3206.3206

Published: 2014

Journal Articles

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Blood (2013) 122 (21): 4352.

https://doi.org/10.1182/blood.V122.21.4352.4352

Published: 2013

Journal Articles

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Craig Reeder, MD, Stephen M Ansell, M.D., Ph.D., Katherine Gano, Amylou C. Dueck, PhD, Christopher Conley, MD, Grzegorz S. Nowakowski, Kelly Curtis, MD, John Camoriano, MD, Jose Leis, MD, PhD, James L Slack, MD, Riccardo Valdez, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Keith Stewart, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2741.

https://doi.org/10.1182/blood.V120.21.2741.2741

Published: 2012

Journal Articles

Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.

Veena Devi Salem Fauble, MD, James L Slack, MD, William Hogan, MD, Vivek Roy, M.D., Jose Leis, MD, PhD, Amylou C. Dueck, PhD, Mark R Litzow, MD, Mrinal M. Patnaik, MBBS, MD, Pardanani Animesh, MBBS, PhD, Candido E. Rivera, MD, Raoul Tibes, MD, PhD, John Camoriano, MD, Roberta H. Adams, MD, Pierre Noel, MD, Nandita Khera, MD, Lisa Sproat, MD, MSW, Ruben A. Mesa

Blood (2012) 120 (21): 2850.

https://doi.org/10.1182/blood.V120.21.2850.2850

Published: 2012

Journal Articles

Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience After FDA Approval

Holly Lynn Geyer, MD, Emily Knight, Keith Cannon, MD, Kathryn Barr, N. P., Raoul Tibes, MD, PhD, John Camoriano, MD, Pierre Noel, MD, Ruben A. Mesa

Blood (2012) 120 (21): 5061.

https://doi.org/10.1182/blood.V120.21.5061.5061

Published: 2012

Journal Articles

Induction Therapy Followed by Allogeneic Stem Cell Transplant for MPN Blast Phase: Outcomes From Mayo Clinic in Arizona

Chad Cherington, MD, James L. Slack, MD, Jose F. Leis, MD, PhD, Roberta H. Adams, MD, Craig B. Reeder, MD, Joseph R. Mikhael, MD, John Camoriano, MD, Pierre Noel, MD, Raoul Tibes, MD, PhD, Jeffrey A. Betcher, R.Ph, Mary E Peterson, C.N.P, Meagan S. Higgins, C.N.P, Ginger Gillette-Kent, C.N.P, Lisa D. Tremblay, N.P, Jane J Olsen, N.P, Ruben A. Mesa, MD

Blood (2011) 118 (21): 1749.

https://doi.org/10.1182/blood.V118.21.1749.1749

Published: 2011

Journal Articles

Pegylated Interferon Alpha – 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases

Krisstina Gowin, DO, Prakash Thapaliya, MD, J Samuelson, MD, C N Harrison, Deepti Radia, MD, Bjorn Andreasson, MD, John Mascarenhas, MD, Alessandro Rambaldi, MD, T Barbui, Catherine J Rea, MD, John Camoriano, MD, A Gentry, NP, Jean-Jacques Kiladjian, MD, PhD, Casey L O'Connell, MD, Ruben A. Mesa, MD

Blood (2011) 118 (21): 2818.

https://doi.org/10.1182/blood.V118.21.2818.2818

Published: 2011

Journal Articles

Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens

Prakash Thapaliya, MBBS, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, David P. Steensma, MD, John Camoriano, MD, Wenting Wu, Susan Geyer, PhD, Ruben A. Mesa, MD

Blood (2010) 116 (21): 4094.

https://doi.org/10.1182/blood.V116.21.4094.4094

Published: 2010

Journal Articles

Fatigue and Daily Life in Patients with Essential Thrombocythemia: Comparisons Between the USA and France in 447 Patients.

Ruben A. Mesa, MD, Jerome Rey, MD, Ayalew Tefferi, MD, Joyce Niblack, JD, Pascal Lenain, Emmanuel Raffoux, MD, Thierry De Revel, MD, PhD, John Camoriano, MD, Jean-Jacques Kiladjian, MD, PhD

Blood (2009) 114 (22): 2904.

https://doi.org/10.1182/blood.V114.22.2904.2904

Published: 2009

Journal Articles

Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era.

Ruben A. Mesa, MD, Susan Schwager, Jocelin Huang, MD, Animesh D. Pardanani, MBBS, PhD, Kebede Hussein, MD, John Camoriano, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 3918.

https://doi.org/10.1182/blood.V114.22.3918.3918

Published: 2009

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Blood (2009) 114 (22): 587.

https://doi.org/10.1182/blood.V114.22.587.587

Published: 2009

NARROW

Integrative Hematology Oncology Fellowship: A Descriptive Analysis of the First Accredited Program in the United States

Predictors of Individual Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study

Patient Cost Savings When Using Telehealth for Management of Myeloproliferative Neoplasms

Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination

Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need

Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results

Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience

Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis

Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.

Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience After FDA Approval

Induction Therapy Followed by Allogeneic Stem Cell Transplant for MPN Blast Phase: Outcomes From Mayo Clinic in Arizona

Pegylated Interferon Alpha – 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases

Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens

Fatigue and Daily Life in Patients with Essential Thrombocythemia: Comparisons Between the USA and France in 447 Patients.

Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only